HLA- B*08 Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-Carbamylated Protein Antibody-Positive/Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis.

[EN] Objective: Previously, only the HLA-DRB1 alleles have been assessed in rheumatoid arthritis (RA). The aim of the present study was to identify the key major histocompatibility complex (MHC) susceptibility factors showing a significant association with anti-carbamylated protein antibody-positive...

Descripción completa

Detalles Bibliográficos
Autores: González, Antonio, Regueiro, Cristina, Casares-Marfil, Desire, Lundberg, Karin, Knevel, Rachel, Acosta-Herrera, Marialbert, Rodriguez-Rodriguez, Luis, Lopez-Mejias, Raquel, Pérez Pampín, Eva, Triguero-Martinez, Ana, Nuño, Laura, Ferraz-Amaro, Ivan, Rodriguez-Carrio, Javier, Lopez-Pedrera, Rosario, Robustillo-Villarino, Montse, Castañeda, Santos, Remuzgo-Martinez, Sara, Alperi, Mercedes, Alegre-Sancho, Juan J, Balsa, Alejandro, Gonzalez-Alvaro, Isidoro, Mera Varela, Antonio, Fernandez-Gutierrez, Benjamin, Gonzalez-Gay, Miguel A, Trouw, Leendert A, Grönwall, Caroline, Padyukov, Leonid, Martin, Javier, González Martínez-Pedrayo, Antonio
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/17701
Acceso en línea:https://pubmed.ncbi.nlm.nih.gov/33381897/
http://hdl.handle.net/20.500.11940/17701
Access Level:acceso abierto
Palabra clave:Anti-Citrullinated Protein Antibodies
Arthritis, Rheumatoid
Autoantibodies
Rheumatology
Arthritis
Population
Protein Carbamylation
HLA-DRB1 Chains
HLA-B8 Antigen
Alleles
autoanticuerpos
antígeno HLA-B8
Carbamilación de Proteína
alelos
reumatología
cadenas HLA-DRB1
artritis reumatoide
artritis
anti-carbamylated protein antibodies
shared epitope
IDIS
CHUS
Descripción
Sumario:[EN] Objective: Previously, only the HLA-DRB1 alleles have been assessed in rheumatoid arthritis (RA). The aim of the present study was to identify the key major histocompatibility complex (MHC) susceptibility factors showing a significant association with anti-carbamylated protein antibody-positive (anti-CarP+) RA. Methods: Analyses were restricted to RA patients who were anti-cyclic citrullinated peptide antibody negative (anti-CCP-), because the anti-CCP status dominated the results otherwise. Therefore, we studied samples from 1,821 anti-CCP- RA patients and 6,821 population controls from Spain, Sweden, and the Netherlands. The genotypes for ~8,000 MHC biallelic variants were assessed by dense genotyping and imputation. Their association with the anti-CarP status in RA patients was tested with logistic regression and combined with inverse-variance meta-analysis. Significance of the associations was assessed according to a study-specific threshold of P < 2.0 × 10-5 . Results: The HLA-B*08 allele and its correlated amino acid variant Asp-9 showed a significant association with anti-CarP+/anti-CCP- RA (P < 3.78 × 10-7 ; I2 = 0). This association was specific when assessed relative to 3 comparator groups: population controls, anti-CarP-/anti-CCP- RA patients, and anti-CCP- RA patients who were positive for other anti-citrullinated protein antibodies. Based on these findings, anti-CarP+/anti-CCP- RA patients could be separated from other antibody-defined subsets of RA patients in whom an association with the HLA-B*08 allele has been previously demonstrated. No other MHC variant remained associated with anti-CarP+/anti-CCP- RA after accounting for the presence of the HLA-B*08 allele. Specifically, the reported association of HLA-DRB1*03 was observed at a level comparable to that reported previously, but it was attributable to linkage disequilibrium. Conclusion: These results identify HLA-B*08 carrying Asp-9 as the MHC locus showing the strongest association with anti-CarP+/anti-CCP- RA. This knowledge may help clarify the role of the HLA in susceptibility to specific subsets of RA, by shaping the spectrum of RA autoantibodies.